## Amendments to the Specification:

Please replace the paragraphs beginning at page 70, line 6 (paragraphs [0438]- [0439] of the published application), with the following amended paragraphs:

## Example-62 : 1- (4-methoxybenzenesulfonyl)-3- (4-methylpiperazin-1-ylmethyl)- 1 H-indole

--Using essentially the same procedure as described in example 53, above derivative was prepared. Melting range (C): 115-117; IR spectra (cm~1): 1125,1170, 1358,1451; Mass (m/z): 400 (M+H) +, 300 (M-piperazine) +; 'H-NMR (ppm): 2.27 (3H, s), 2.44 (8H, bs), 3.60 (2H, s), 3.78 (3h, s), 6.84-6. 88 (2H, m), 7.21-7. 31 (2H, m), 7.46 (1H, s), 7.65-7. 69 (1H, dd), 7.78-7. 83 (2H, m), 7.93-7. 97 (1H, d, J = 7.6 Hz). [[1-(2-]]

## <u>Example-62 : 1-(2</u>- Bromo-4-methoxybenzenesulfonyl)-5-chloro-2-methyl-3- (4-methylpiperazin-1-ylmethyl)-1 H-indole

Using essentially the same procedure as described in example 16, and D169, above derivative was prepared. Mass (m/z) : 526 (M+H)<sup>+</sup>, 528 (M+H)<sup>+</sup> --